Quality of Life After Isolated Limb Infusion for In-Transit Melanoma of the Extremity

Betty S. Jiang, Paul J. Speicher, Samantha Thomas, Paul J. Mosca, Amy P. Abernethy, Douglas Tyler

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background: Isolated limb infusion (ILI) has been associated with persistent edema, numbness, pain, and functional impairment of the treated limb. However, health-related quality of life (HRQOL) has not yet been assessed using a validated questionnaire. Methods: Functional Assessment of Cancer Therapy-Melanoma (FACT-M) questionnaires were collected from subjects enrolled a phase I ILI trial with temozolomide at baseline and 2, 6 weeks, and 3 months post-ILI. Of 28 enrolled patients, 19 patients received maximum tolerated dose of temozolomide and are included in the HRQOL analysis. Clinical and operative variables and treatment response data also were collected. Results: HRQOL scores showed a trend of improvement from baseline through 3-months post-ILI as measured by FACT-M and the melanoma surgery scores. There were no differences in HRQOL when patients were stratified by disease burden, clinical toxicity level, and 3-month disease response. Additionally, fewer patients complained of pain, numbness, and swelling of the affected limb at 3 months post-ILI compared to baseline, and also these symptoms were improved at the immediate postoperative visit compared with baseline. Conclusions: Despite the known morbidity of ILI, we have demonstrated with a validated HRQOL questionnaire that HRQOL is not adversely impacted at therapeutic doses of temozolomide delivered intra-arterially from baseline through 3 months posttreatment. Patient centered-outcomes should be evaluated as a standard part of all future regional therapy trials using standardized melanoma-specific HRQOL questionnaires to more completely evaluate the utility of this type of treatment strategy.

Original languageEnglish (US)
Pages (from-to)1694-1700
Number of pages7
JournalAnnals of Surgical Oncology
Volume22
Issue number5
DOIs
StatePublished - May 1 2015
Externally publishedYes

Fingerprint

Melanoma
temozolomide
Extremities
Quality of Life
Hypesthesia
Therapeutics
Pain
Maximum Tolerated Dose
Edema
Neoplasms
Morbidity
Surveys and Questionnaires

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Quality of Life After Isolated Limb Infusion for In-Transit Melanoma of the Extremity. / Jiang, Betty S.; Speicher, Paul J.; Thomas, Samantha; Mosca, Paul J.; Abernethy, Amy P.; Tyler, Douglas.

In: Annals of Surgical Oncology, Vol. 22, No. 5, 01.05.2015, p. 1694-1700.

Research output: Contribution to journalArticle

Jiang, Betty S. ; Speicher, Paul J. ; Thomas, Samantha ; Mosca, Paul J. ; Abernethy, Amy P. ; Tyler, Douglas. / Quality of Life After Isolated Limb Infusion for In-Transit Melanoma of the Extremity. In: Annals of Surgical Oncology. 2015 ; Vol. 22, No. 5. pp. 1694-1700.
@article{ec7ca06cea0f4907bb822cbf427eccf5,
title = "Quality of Life After Isolated Limb Infusion for In-Transit Melanoma of the Extremity",
abstract = "Background: Isolated limb infusion (ILI) has been associated with persistent edema, numbness, pain, and functional impairment of the treated limb. However, health-related quality of life (HRQOL) has not yet been assessed using a validated questionnaire. Methods: Functional Assessment of Cancer Therapy-Melanoma (FACT-M) questionnaires were collected from subjects enrolled a phase I ILI trial with temozolomide at baseline and 2, 6 weeks, and 3 months post-ILI. Of 28 enrolled patients, 19 patients received maximum tolerated dose of temozolomide and are included in the HRQOL analysis. Clinical and operative variables and treatment response data also were collected. Results: HRQOL scores showed a trend of improvement from baseline through 3-months post-ILI as measured by FACT-M and the melanoma surgery scores. There were no differences in HRQOL when patients were stratified by disease burden, clinical toxicity level, and 3-month disease response. Additionally, fewer patients complained of pain, numbness, and swelling of the affected limb at 3 months post-ILI compared to baseline, and also these symptoms were improved at the immediate postoperative visit compared with baseline. Conclusions: Despite the known morbidity of ILI, we have demonstrated with a validated HRQOL questionnaire that HRQOL is not adversely impacted at therapeutic doses of temozolomide delivered intra-arterially from baseline through 3 months posttreatment. Patient centered-outcomes should be evaluated as a standard part of all future regional therapy trials using standardized melanoma-specific HRQOL questionnaires to more completely evaluate the utility of this type of treatment strategy.",
author = "Jiang, {Betty S.} and Speicher, {Paul J.} and Samantha Thomas and Mosca, {Paul J.} and Abernethy, {Amy P.} and Douglas Tyler",
year = "2015",
month = "5",
day = "1",
doi = "10.1245/s10434-014-3979-9",
language = "English (US)",
volume = "22",
pages = "1694--1700",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "5",

}

TY - JOUR

T1 - Quality of Life After Isolated Limb Infusion for In-Transit Melanoma of the Extremity

AU - Jiang, Betty S.

AU - Speicher, Paul J.

AU - Thomas, Samantha

AU - Mosca, Paul J.

AU - Abernethy, Amy P.

AU - Tyler, Douglas

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Background: Isolated limb infusion (ILI) has been associated with persistent edema, numbness, pain, and functional impairment of the treated limb. However, health-related quality of life (HRQOL) has not yet been assessed using a validated questionnaire. Methods: Functional Assessment of Cancer Therapy-Melanoma (FACT-M) questionnaires were collected from subjects enrolled a phase I ILI trial with temozolomide at baseline and 2, 6 weeks, and 3 months post-ILI. Of 28 enrolled patients, 19 patients received maximum tolerated dose of temozolomide and are included in the HRQOL analysis. Clinical and operative variables and treatment response data also were collected. Results: HRQOL scores showed a trend of improvement from baseline through 3-months post-ILI as measured by FACT-M and the melanoma surgery scores. There were no differences in HRQOL when patients were stratified by disease burden, clinical toxicity level, and 3-month disease response. Additionally, fewer patients complained of pain, numbness, and swelling of the affected limb at 3 months post-ILI compared to baseline, and also these symptoms were improved at the immediate postoperative visit compared with baseline. Conclusions: Despite the known morbidity of ILI, we have demonstrated with a validated HRQOL questionnaire that HRQOL is not adversely impacted at therapeutic doses of temozolomide delivered intra-arterially from baseline through 3 months posttreatment. Patient centered-outcomes should be evaluated as a standard part of all future regional therapy trials using standardized melanoma-specific HRQOL questionnaires to more completely evaluate the utility of this type of treatment strategy.

AB - Background: Isolated limb infusion (ILI) has been associated with persistent edema, numbness, pain, and functional impairment of the treated limb. However, health-related quality of life (HRQOL) has not yet been assessed using a validated questionnaire. Methods: Functional Assessment of Cancer Therapy-Melanoma (FACT-M) questionnaires were collected from subjects enrolled a phase I ILI trial with temozolomide at baseline and 2, 6 weeks, and 3 months post-ILI. Of 28 enrolled patients, 19 patients received maximum tolerated dose of temozolomide and are included in the HRQOL analysis. Clinical and operative variables and treatment response data also were collected. Results: HRQOL scores showed a trend of improvement from baseline through 3-months post-ILI as measured by FACT-M and the melanoma surgery scores. There were no differences in HRQOL when patients were stratified by disease burden, clinical toxicity level, and 3-month disease response. Additionally, fewer patients complained of pain, numbness, and swelling of the affected limb at 3 months post-ILI compared to baseline, and also these symptoms were improved at the immediate postoperative visit compared with baseline. Conclusions: Despite the known morbidity of ILI, we have demonstrated with a validated HRQOL questionnaire that HRQOL is not adversely impacted at therapeutic doses of temozolomide delivered intra-arterially from baseline through 3 months posttreatment. Patient centered-outcomes should be evaluated as a standard part of all future regional therapy trials using standardized melanoma-specific HRQOL questionnaires to more completely evaluate the utility of this type of treatment strategy.

UR - http://www.scopus.com/inward/record.url?scp=84939896997&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939896997&partnerID=8YFLogxK

U2 - 10.1245/s10434-014-3979-9

DO - 10.1245/s10434-014-3979-9

M3 - Article

C2 - 25120251

AN - SCOPUS:84939896997

VL - 22

SP - 1694

EP - 1700

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 5

ER -